Table of Contents
Nigerian tycoon Fidelis Ayebae’s Fidson Healthcare lifted its nine-month profit by 47%, as strong sales growth and a sharp drop in currency losses more than offset rising operating costs.
Profit after tax rose to N11.74 billion ($8.8 million) in the nine months to Sept. 30, from N7.97 billion a year earlier, Nairametrics reported on Wednesday. Pre-tax profit climbed 49.5% to N17.79 billion.
Revenue grew 21% to N112.61 billion ($84.8 million), and gross profit rose 28.1% to N48.94 billion. Operating profit increased 25.4% to N21.24 billion. That lifted the company’s gross margin to about 43.5% of sales.
A calmer currency market helped. Net foreign exchange losses fell to just N104.28 million, from N4.16 billion a year earlier, and finance costs dropped 27.4% to N3.73 billion. The smaller currency hit alone was worth about N4 billion to pre-tax profit compared with the same period last year.
Costs rose sharply as the drugmaker expanded. Administrative expenses jumped 65.8% to N16.42 billion, while selling and distribution expenses rose 50.2% to N11.51 billion. Income tax expense increased 54% to N6.05 billion, an effective rate of about 34%.
The third quarter was the strongest part of the period. Revenue for the three months rose 25.3% to N38.13 billion, while pre-tax profit more than doubled, up 109.3% to N6.09 billion. Profit after tax rose 106.2% to N4.02 billion, and operating profit for the quarter grew 43.5% to N6.86 billion.
Investors have rewarded the growth. Fidson shares closed at N83.50 on Tuesday, up about 66.7% this year from N50.10, and rose a further 4.4% to N87.15 by midday on Wednesday. The stock ranks 32nd on the Nigerian Exchange by year-to-date performance.
The results add to a strong run for the company Ayebae founded. Fidson reported record annual revenue of N119 billion last year and is targeting sub-Saharan Africa’s biggest drug factory as it expands its manufacturing base.
It has also been raising fresh capital. Earlier this year, Fidson sought $12.9 million in new funding and received $15.2 million in demand from investors, a sign of confidence in its expansion plans.
With nine-month revenue already close to last year’s full-year total, Fidson is on course for another record year.
Ayebae founded Fidson in 1995 and built it into one of Nigeria’s largest listed pharmaceutical companies. The rise in the share price this year has also lifted the value of his stake in the company, which topped $21 million late last year.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story — the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now